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Abstract HL-60 acute myeioblastic and U937 monoblastoid 
lenkaemic cell lines both cleave poly(ADP-ribose)polymerase 
(PARP), at the onset of apoptosis, in response to a wide range of 
cytotoxic agents. This appears to be a common feature of 
leukaemic cell apoptusis. However, in the chronic myelogenous 
leukaemic (CML) derived cell line, K562, no such cleavage was 
detectable. This correlated with previous findings that this cell 
line is particularly resistant to apoptosis induced by cytotoxic 
agents. Proteolytic cLeavage of PARP and the subsequent 
progression to apoptosis was inhibited by two protease inhihiturs 
NEM and IOD. As both PARP cleavage and DNA fragmenta- 
tion appeared cLosely linked in these cell lines, anti-oxidants 
(previously shown to be effective inhibitors of DNA fragmenta- 
tion and apoptosis) were also demonstrated to prevent PARP 
cleavage. These results combine to suggest that ROI may 
mediate PARP cleavage, DNA fragmentation and the eventual 
apoptosis of these cells following cytotoxic insult. 
Key words: Reactive oxygen intermediates; Apoptosis; 
Poly(ADP-ribose)polymerase 
1. Introduction 
Apoptosis is a regulated process, allowing the selective lim- 
ination of cells in an orderly fashion [1,2]. It occurs both 
during normal development [3,4] and as a result of a diverse 
range of cytotoxic insults [5,6]. There is also compelling evi- 
dence implicating apoptotic cell death as a factor during 
AIDS, human neurodegenerative diseases, autoimmunity 
and oncogenesis [7,8]. 
However, the biochemistry and molecular control of apop- 
tosis remain to be delineated. The biochemical event most 
intensively studied has been endonuclease activity [9,10]. The 
recent discovery of a family of cysteine proteases, closely re- 
lated to Ced-3, has identified another biochemical participant 
of apoptosis [11,12]. These proteases include ICE, CPP-32/ 
Yama/apopain, ICH1/Nedd-2, TX/ICH-2, MCH-2, -3 
and -4 and MIH-1, each of which induce apoptosis once ex- 
pressed [13]. They exist as inactive precursors and remain so 
until activated by a specific processing event [13,14]. Several of 
these proteases activate or inactivate one another and so a 
cascade effect involving one or more has been envisaged 
[13]. These proteases cleave a number of substrates which 
may contribute to eventual cell death. These include the 70 
kDa protein component of small nuclear ribonucleoprotein 
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U1, lamin B1, ct fodrin, topoisomerase 1, [3-actin and poly- 
(ADP-ribose)polymerase or PARP [13,14]. 
The protease CPP-32 has been directly linked to apoptosis 
[15,16]. In addition, this protease together with MCH-3 re- 
sembles Ced-3 most closely in sequence homology and sub- 
strate specificity [17]. Both of these proteases pecifically 
cleave the DNA repair enzyme PARP as an early apoptotic 
event. PARP cleavage has been linked to endonuclease activa- 
tion, with PARP demonstrated to negatively regulate ndonu- 
clease activity [19]. On cleavage of PARP, this block is re- 
moved and the endonuclease re-activated uring apoptosis 
[19]. PARP itself functions as a molecular nick sensor [20]. 
Cleavage of PARP results in decreased enzyme activity which 
precludes binding of the enzyme to the damaged site and thus 
compromises the response to DNA damage [20,21]. 
Previously in our laboratory, we have demonstrated the 
rapid production of peroxide during apoptosis in HL-60 and 
U937 leukaemic ell lines [22]. Furthermore, a number of anti- 
oxidant compounds prevented DNA fragmentation a d apop- 
tosis in these cell lines [23,24]. As mentioned above, PARP 
cleavage has been linked to endonuclease activity and DNA 
fragmentation. Therefore, we investigated PARP cleavage in 
HL-60, U937 and K562 cell lines with particular emphasis 
being given to the role of ROI during PARP cleavage. In 
conjunction with earlier reports, the cleavage of PARP, 
DNA fragmentation and subsequent apoptosis were common 
events on addition of cytotoxic agents. To establish further 
that PARP cleavage and DNA fragmentation follow the same 
common pathway to apoptosis, protease inhibitors were tested 
against both PARP cleavage and DNA fragmentation. Given 
the protection observed with anti-oxidants against DNA frag- 
mentation and apoptosis in these cells [22-24], we screened a
range of anti-oxidants for the ability to prevent PARP cleav- 
age. Our results indicate that both of these events (PARP 
cleavage and DNA fragmentation) occur following ROI pro- 
duction and suggest that ROI may act as common mediators, 
for PARP cleavage, DNA fragmentation and the eventual 
apoptosis of these leukaemic ells. 
2. Materials and methods 
2.1. Cell culture conditions 
The human HL-60 acute myeloblastic leukaemic ell line, the U937 
monoblastoid cell line and K562, a CML derived cell line, were used 
in the present study [25-27]. Cells were cultured in RPMI 1640 med- 
ium (Gibco, UK), supplemented with 10% FCS (Biochom KG, Ger- 
many) and 1% penicillin/streptomycin (Gibco, UK). Cells were main- 
tained at 37°C in a humidified 5% CO2 atmosphere. 
2.2. Cell viability and morphology 
Cell number was determined using a Neubauer haemocytometer 
and viability was assessed by their ability to exclude trypan blue. 
Cell morphology was assessed by staining cytocentrifuge preparations 
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with Rapi-Diff II (Paramount Reagents Ltd, UK). Apoptotic cells 
were identified by examining the changes in forward and side scatter 
using a FACScan flow cytometer (Becton-Dickinson, USA) equipped 
with Lysis II software [23]. 
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2.3. UV- and drug-induced apoptosis 
Apoptosis was induced in HL-60 and U937 cells by exposure to UV 
irradiation as previously described [23]. Briefly, cells (106/ml) were 
seeded in polystyrene 24-well plates (Nunc, Roskilde Denmark) and 
exposed from below to a 302 nm UV transilluminator source at a 
distance of 2.5 crn for 10 min at room temperature. Cells were then 
returned to 37°C and assessed for apoptosis at appropriate time per- 
iods. Actinomycin D (Act-D., 5 I.tg/ml), camptothecin (Camp., 5 ~tg/ 
ml), etoposide (Etop., 25 ~tg/ml) were added. These agents were sup- 
plied by Sigma Chemical Co. (St. Louis) and stock solutions were 
prepared in DMSO. Chlorambucil (Chlor., 50 ~tM) and melphalan 
(Melp., 50 p.M) were also used and 0.1 M stocks were prepared in 
DMSO. Hydrogen peroxide (0.5 mM) was also added to induce apop- 
tosis and this was obtained from BDH Chemicals. As a positive con- 
trol for PARP cleavage, Jurkat T-cells were treated with 1 ~tg/ml anti- 
Fas antibody for 2 h (anti-Fas CH-11 IgM, Medical and Biological 
Laboratories, USA). Anti-oxidants were prepared as previously de- 
scribed [22-24] and the ones chosen were zinc chloride, 1 M in 0.15 
saline, pyrrolidine dithiocarbamate (PDTC), 1 M in distilled water, 
butylated hydroxyanisole (BHA) and phenanthroline (Phen.), 1 M in 
ethanol, 2,2,6,6-tetramethylpiperidinoxyl (Tempo.) and 313-doxyl-5a- 
cholestane (Dox.), 1 M in DMSO. 
2.4. DNA isolation and electrophoresis 
DNA was isolated and treated in the manner described previously 
[28]. Briefly, cells were pelleted by centrifugation at200 x g for 5 min 
at room temperature. The pellets were re-suspended in 20 gl lysis 
buffer and 10 I11 RNase A and then incubated at 37°C for 18 h. 
Proteinase K (10 I.tl) was then added and samples incubated at 50°C 
for 2 h. DNA electrophoresis was carried out for 4 h at 55 V as 
previously described [23,28]. 
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Fig. 1. Production of the 29 kDa PARP cleavage product in (A) 
HL-60 cells that were (1) UV treated 30 min, (2) UV treated 2 h, 
(3) Act-D. 30 min, (4) Act-D. 2 h, (5) Camp. 30 min, (6) Camp. 2 h, 
(7) untreated 30 min, (8) untreated 2 h, (9) Jurkat cells treated with 
1 Ixg/ml anti-Fas antibody for 2 h. The time points 30 min and 2 h 
refer to the incubation times, following cytotoxic addition, at which 
PARP cleavage was determined. (B) HL-60 cells lanes (1-5) and 
U937 cells lanes (6-10) at 2 h: (1) untreated, (2) Chlor., (3) Etop., 
(4) H202, (5) Melp., (6) Chlor., (7) Etop., (8) H202, (9) Melp., 
(10) untreated, (C) K562 cells at 2 h (1) UV, (2) Act-D., (3) Camp., 
(4) Etop., (5) H202, (6) Chlor., (7) Melp., (8) untreated, (9) Jurkat 
cells treated with 1 ~tg/ml anti-Fas antibody (10) untreated Jurkat 
cells. 
Melp. Peroxide levels were measured using a Becton Dickinson 
FACScan flow cytometer. An increase in FL1-H fluorescence corre- 
lates with increased peroxide production. 
3. Results 
2.5. DNA nick-end labelling (TUNEL) 
For in situ terminal deoxynucleotidyl transferase-mediated labelling 
of DNA nick-ends, we used an improved version of the assay pre- 
viously described by Gorczyca et al. [29]. Briefly, cells were fixed in 
1% paraformaldehyde and stored overnight at -200C. After washing 
in PBS, cells were re-suspended in 50 p.l of reaction mixture. This 
mixture was incubated at 37°C for 30 rain. Cells were then washed 
in PBS and re-suspended in 100 I11 of staining buffer. Cells were 
subsequently incubated for 30 min at room temperature in the dark. 
Stained cells were rinsed in PBS before analysis for fluorescence using 
a Becton Dickinson FACScan [24]. Bio-16-dUTP and the TdT-en- 
zyme were obtained from Boehringer Mannheim. All other chemicals 
were obtained from Sigma. 
2.6. Immunoblotting for PARP cleavage products 
The analysis of PARP cleavage was performed using the method 
previously described by Kaufmann et al. [18]. Briefly, 1 × 106 cells 
were used per sample; these were centrifuged and washed in PBS. 
Next 40 I.tl of sample buffer (containing 50 mM Tris, pH 6.8, 6 M 
urea, 6% [~-mercaptoethanol, 0.003% bromophenol b ue and 3% SDS) 
was added and the samples onicated. These were then heated at 80°C 
for 5 min and samples ubsequently loaded and run on a 10% SDS- 
PAGE gel for 1 h at 140 V. After electrophoretic transfer of the 
separated polypeptides to nitrocellulose, the membrane was probed 
with an antibody Anti-F2 (generously provided by Dr. G. deMurcia, 
Centre National de la Recherche Scientifique, Strasbourg Cedex, 
France) which is a rabbit polyserum raised against a synthetic peptide 
corresponding to the second zinc finger of human PARP. Detection of 
bound antibody was performed using an enhanced chemiluminescent 
blotting detection system (ECL, Amersham Corp., UK) which was 
then visualised by exposure to auto-radiographic film. 
2. 7. Measurement of intracellular peroxides 
Peroxide levels were assessed using the method of Hockenbery et al. 
[30]. Briefly, cells (5x105/ml) were loaded with 5 ~tM DCFH/DA 
(Molecular Probes, UK, dissolved at 2000× in DMSO) for 1 h at 
37°C prior to cytotoxic insult. The apoptosis-inducing a ents used 
were UV irradiation, H202, Act-D., Camp., Etop., Chlor. and 
3.1. PARP cleavage during leukaemic ell apoptosis 
PARP cleavage has been associated with the onset of apop- 
tosis in several model systems [15,16,18]. In the present study, 
using three leukaemic ell lines, the formation of the 29 kDa 
PARP cleavage product was demonstrated to follow cytotoxic 
insult (Fig. 1A,B). The cytotoxic agents used were UV irradia- 
tion, actinomycin D, camptothecin, etoposide, chlorambucil, 
melphalan and hydrogen peroxide. These agents were used at 
concentrations known to produce apoptosis (50-60%) in these 
cells after a 4 h incubation. The formation of the 29 kDa 
PARP fragment mirrors the decay of the intact enzyme (116 
kDa) and therefore only this band is shown for the purposes 
of clarity. Time course experiments established the 2 h time 
point as the earliest ime at which PARP cleavage was visible 
with these cytotoxic agents (data not shown). Similar results 
were obtained using either human HL-60 acute myeloblastic 
cells or U937 monocytes. 
3.2. DNA fragmentation and PARP cleavage 
From Fig. 1C, it is clear that none of the cytotoxic agents 
were capable of cleaving PARP in the K562 human CML cell 
line. This cell line exhibits a marked resistance to apoptosis 
when subjected to cytotoxic insult with no DNA fragmenta- 
tion evident [31]. 
As mentioned above, these agents at the concentrations 
used, induce apoptosis to a similar degree. Therefore, between 
2 and 4 h after cytotoxic insult, an increasing percentage of 
apoptosis was visible morphologically, by DNA gel electro- 
phoresis and by in situ nick end-labelling (Fig. 2A-C). How- 
ever, in all cases, these cytotoxic agents first induced PARP 
cleavage then DNA fragmentation. This confirmed the order 
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of these two events in these leukaemic ells. Figs. 1 and 2 
illustrate that the proteolytic leavage of PARP occurs prior 
to endonuclease activation and before any morphological 
signs of apoptosis are evident. It also suggests that both 
events are closely associated, with cleavage resulting in frag- 
mentation. 
A 
3.3. Protease involvement during apoptosis 
The ability of CTLs and NK cells to kill target cells using 
proteases was an early indication of the importance of these 
enzymes during apoptosis [13]. To distinguish the specific in- 
volvement of these cysteine proteases, above any other, during 
apoptosis, researchers have compiled an inhibitor profile 
[15,16]. A number of inhibitors can block the cleavage site 
of PARP, thus preventing PARP cleavage and the subsequent 
apoptosis. More recently, through the use of specific inhibi- 
tors, CPP-32 was identified as the protease responsible for 
PARP cleavage [16]. Therefore, using two of these protease 
inhibitors, NEM and IOD, effective inhibition of UV-induced 
PARP cleavage, DNA fragmentation and subsequent apopto- 
sis was achieved (Fig. 3A,B). These results indicated the im- 
portance of these cysteine proteases during DNA fragmenta- 
tion and apoptosis. 
3.4. ROI, PARP cleavage and apoptosis 
The protection afforded by anti-oxidants against leukaemic 
cell apoptosis and the apparent link between PARP cleavage 
and apoptosis prompted an investigation of the role of ROI 
during PARP cleavage. In conjunction with this, anti-oxidant 
addition, bcl-2 or CrmA expression provided similar protec- 
tion against TNFqx-induced apoptosis [32]. This suggested 
that CrmA (and possibly other protease inhibitors) may act 
in a similar fashion to bcl-2 and other anti-oxidants in order 
to prevent cell death. 
We utilised the following anti-oxidants, previously shown to 
inhibit apoptosis in our cell lines [22-24], zinc chloride, 
PDTC, Dox., Tempo., BHA, and Phen. Peroxide production 
was detected as early as 10-15 min in HL-60 cells and this was 
evident with all of the cytotoxic agents used in this study (Fig. 
4A). From Fig. 4B, the protection afforded by these anti-oxi- 
dants against PARP cleavage is obvious. The extensive corre- 
lation between PARP cleavage and subsequent apoptosis was 
once again evident as these inhibitors were effective against 
both the proteolytic leavage of PARP and endonuclease ac- 
tivation. 
The results from Fig. 4 identify ROI production as the 
earliest detectable change in leukaemic ells undergoing apop- 
tosis. ROI production led to PARP cleavage then DNA frag- 
mentation and apoptosis, all of these events were prevented 
using anti-oxidants. This is in agreement with the most recent 
results from our laboratory which suggest ROI production 
may mediate leukaemic apoptosis following cytotoxic insult 
[22]. 
Fig. 2. (A) Morphology of: (1) untreated HL-60 cells and (2) 
Camp. treated cells, both taken after 3 h in culture. (B) DNA gel 
electrophoresis of: (lane A) untreated HL-60 3 h, (lane B) Camp. 
treated 2 h, (lane C) Camp. treated 3 h. (C) Tunel method on: 
(1) untreated HL-60 cells 3 h, (2) Camp. treated 2 h, (3) Camp. 
treated 3 h. 
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4. Discussion 
The biochemical machinery required to initiate the pro- 
gramme for cell death is gradually being realised. Previous 
efforts were directed at the identification of the enzyme(s) 
responsible for the DNA fragmentation associated with apop- 
tosis [2,9]. However, more recent results have shifted the em- 
phasis from nuclear to cytoplasmic based components of the 
cell death process [13,14]. Early evidence suggesting the in- 
volvement of proteases during apoptosis arose from the rea- 
lisation that CTLs and NK cells could kill using proteases. In 
conjunction with this, the results with ted-3 related mamma- 
lian proteases suggest that the cytoplasm ay contain critical 
components of the apoptotic cascade [13]. This has been 
clearly established in cell free systems [33,34]. 
In this study, we have demonstrated PARP cleavage as a 
common factor in response to cytotoxic insult in both HL-60 
and U937 cells. This cleavage occurred prior to any other of 
the associated features of apoptosis uch as DNA fragmenta- 
tion and morphological deterioration. However, in the CML 
derived K562 cell line, previously shown to be extremely re- 
sistant o cytotoxic insult [31], no PARP cleavage was detect- 
able with any of the cytotoxic agents screened. These agents 
also failed to produce DNA fragmentation i this cell line 
[31]. This shows the close correlation between PARP cleavage 
and subsequent endonuclease activation. This correlation has 
been linked to the inhibitory effect of PARP activity on en- 
donuclease activity [19]. Once PARP is cleaved, this block is 
removed and the endonuclease is re-activated under these cir- 
cumstances [19]. 
The specific involvement of these cysteine proteases has 
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Fig. 3. (A) Dose-response inhibition of UV-induced apoptosis using 
NEM and IOD. Cells were either UV treated plus inhibitors (NEM 
+/IOD +) or treated with inhibitors alone (NEM/IOD). Apoptosis 
was assessed at 3 h. (B) Dose-dependent i hibition of UV-induced 
PARP cleavage in HL-60 cells by IOD lanes (2~,) and NEM lanes 
(5 7). (1) UV (positive control), (2) UV+250 /.tM IOD, (3) UV+50 
p.M IOD, (4) UV+10 ~tM IOD, (5) UV+250 ktM NEM, (6) UV+50 
~M NEM, (7) UV+10 [.tM NEM, (8) untreated control cells. 
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Fig. 4. (A) Peroxide production, which correlates with an increase 
in FL1-H fluorescence, was assessed 15 min following cytotoxic in- 
sult. (1) Untreated, (2) Act-D. treated, (3) UV treated. The other 
cytotoxic agents also produced peroxide to varying degrees (data 
not shown). (B) Inhibition of UV-induced PARP cleavage by a var- 
iety of anti-oxidants at 2 h. (1) Dox. 1 raM, (2) Zn 1 mM, 
(3) PDTC 40 gM, (4) Tempo. 1 mM, (5) BHA 200 gM, (6) Phen. 
1 mM, (7) UV 10 min, (8) untreated HL-60 cells. 
been established uring apoptosis [15,16]. These experiments 
were required to distinguish these particular proteases from 
others such as proteinase K, fragmentin or chymotrypsin 
which will also induce apoptosis [35]. The use of specific in- 
hibitors helped to identify the cysteine proteases as central 
components of the apoptotic process [15,16]. During the 
course of our work, effective inhibition of PARP cleavage 
and the resultant apoptosis were achieved using the protease 
inhibitors, NEM and IOD. 
Recently, we have proposed ROI as a common mediator of 
apoptosis following cytotoxic insult to these leukaemic ells 
[22]. In this present study, beth PARP cleavage and endonu- 
clease activity appeared as closely associated events. As a 
result, we hypothesised that ROI may mediate both PARP 
cleavage and DNA fragmentation. In several earlier instances, 
we have successfully inhibited apoptosis using a range of anti- 
oxidants [22-24]. The involvement of reactive oxygen inter- 
mediates (ROI) was further implicated during apoptosis 
when it was observed that HzO2 production followed cyto- 
toxic insult. This H202 production was detectable as early as 
10 15 min following cytotoxic insult. 
As a continuation of this earlier work, the present study 
demonstrated that peroxide production preceded PARP cleav- 
age and furthermore, a number of anti-oxidants successfully 
prevented the cleavage of this enzyme. This suggested that 
peroxide was a common mediator of several of the biochem- 
ical events leading to apoptosis. In agreement with this, direct 
addition of hydrogen peroxide also induced PARP cleavage 
and apoptosis in these cells. Peroxide production has also 
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been recently reported uring dexamethasone-induced apop- 
tosis in thymocytes suggesting that oxygen radical production 
due to cytotoxic insult may be quite a common occurrence 
[36]. A similar report demonstrated anti-oxidant disruption in 
Jurkat cells and thymocytes during apoptosis [37]. In many 
model systems, oxidative stress has been linked to perturba- 
tion of the mitochondrial membrane which is a recognised site 
for oxygen radical generation [38]. To the contrary, we have 
found that mitochondrial membrane depolarisation does not 
appear to be a potential source of ROI in these cell lines [22]. 
Regardless of the growing number of reports, the relation- 
ship between oxidative stress and proteases has received scant 
attention. A report indirectly linking oxidative stress and pro- 
teases arose from the work of Talley and colleagues [32]. They 
demonstrated that TNF-tx-induced apoptosis involved ROI 
formation which was effectively blocked by addition of an 
anti-oxidant (NAC) or by the overexpression of bcl-2 or 
crmA. This may suggest that bcl-2 and crmA were functioning 
as anti-oxidants. More direct evidence by Grune and co-work- 
ers [39] demonstrated that oxidatively modified proteins were 
more prone to proteolytic degradation and so this may ex- 
plain the protection observed with anti-oxidants against 
PARP cleavage in our experiments. In line with this, cera- 
mide-induced PARP cleavage was prevented using Bcl-2. Cer- 
amide can provoke ROI production and so this inhibitory 
effect may be a direct result of the anti-oxidant ability of 
Bcl-2. 
In the present study, the overall results established the early 
involvement of proteases during leukaemic ell apoptosis and 
provide further evidence that the cleavage of PARP is a com- 
mon event following cytotoxic insult. We demonstrated a 
close association between PARP cleavage and subsequent en- 
donuclease activation and suggest a common mediator, ROI, 
exists in these cells. ROI induced a number of the biochemical 
events detected, including PARP cleavage and DNA fragmen- 
tation. We have also recently reported the activation of the 
redox sensitive transcription factor NF-~B, by ROI, during 
apoptosis [22]. Furthermore, anti-oxidants prevented both 
NF-~B activation and the subsequent apoptosis in HL-60 
leukaemic ells. Early detection of peroxide in these cell lines 
also suggest hat anti-oxidants may act at the onset of the 
process and so these ROI and/or the sources of this ROI 
production may represent sites for therapeutic intervention 
and manipulation of cell death [22,38]. 
The discovery of cytoplasmic components of a process that 
was largely focused on nuclear events suggests that crucial 
pieces of the apoptotic puzzle are finally being realised. In 
addition, the observation that a growing number of cell lines 
experience changes in cellular edox status during the onset of 
apoptosis, may suggest a more general role for ROI in the 
regulation of apoptosis. 
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